Targeting senescence-associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes

Se Ik Kim; Sangick Park; Eunyong Ahn; Jeunhui Kim; HyunA Jo; Juwon Lee; Untack Cho; Maria Lee; Cheol Lee; Danny N. Dhanasekaran; Taejin Ahn; Yong Sang Song

doi:10.1002/ctm2.1774

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (9) : e1774 DOI: 10.1002/ctm2.1774

LETTER TO THE JOURNAL

Targeting senescence-associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes

Author information +

¹. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea

². Department of Advanced Green Energy and Environment, Handong Global University, Pohang, South Korea

³. Research Group, Foretell My Health, Pohang, South Korea

⁴. Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

⁵. Department of Agricultural Biotechnology, WCU Biomodulation, Seoul National University, Seoul, South Korea

⁶. Interdisciplinary Program in Cancer Biology, Seoul National University College of Medicine, Seoul, South Korea

⁷. Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea

⁸. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

⁹. Department of Life Science, Handong Global University, Pohang, South Korea

¹⁰. Department of Obstetrics and Gynaecology, Myongji Hospital, Hanyang University College of Medicine, Goyang, South Korea

taejin.ahn@handong.edu

yssong@snu.ac.kr

Show less

History +

PDF

Cite this article

Download citation ▾

Se Ik Kim, Sangick Park, Eunyong Ahn, Jeunhui Kim, HyunA Jo, Juwon Lee, Untack Cho, Maria Lee, Cheol Lee, Danny N. Dhanasekaran, Taejin Ahn, Yong Sang Song. Targeting senescence-associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes. Clinical and Translational Medicine, 2024, 14(9): e1774 DOI:10.1002/ctm2.1774

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[2]	O’Donnell RL, McCormick A, Mukhopadhyay A, et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS One. 2014;9(6):e90604.

[3]	Hwangbo S, Kim S, Kim J, et al. Development of machine learning models to predict platinum sensitivity of high-grade serous ovarian carcinoma. Cancers. 2021;13(8):1875.

[4]	Schwarz RF, Ng C, Cooke SL, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015;12(2):e1001789.

[5]	Dong A, Lu Y, Lu B, et al. Genomic/epigenomic alterations in ovarian carcinoma: translational insight into clinical practice. J Cancer. 2016;7(11):1441-1451.

[6]	Peres LC, Leitzinger CC, Sinha S, et al. Racial differences in the tumor immune landscape and survival of women with high-grade serous ovarian carcinoma. Cancer Epidemiol Biomarkers Prev. 2022;31(5):1006-1016.

[7]	Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489-494. doi:10.1038/nature14410

[8]	Sun J, Bao S, Xu D, et al. Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy. Cell Death Dis. 2019;10(9):661.

[9]	Zhang Y, Cao L, Nguyen D, et al. TP53 mutations in epithelial ovarian cancer. Transl Cancer Res. 2016;5(6):650-663. 10.21037/tcr.2016.08.40

[10]	Dimitrova N, Nagaraj AB, Raz A, et al. InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer. Oncogene. 2017;36(17):2472-2482.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.